2013
DOI: 10.1158/1078-0432.ccr-12-1558
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Purpose EMT has been associated with metastatic spread and EGFR inhibitor resistance. We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using NSCLC cell lines and patients treated in the BATTLE study. Methods We conducted an integrated gene expression, proteomic, and drug response analysis using cell lines and tumors from NSCLC patients. A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

55
860
5
5

Year Published

2013
2013
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 842 publications
(925 citation statements)
references
References 44 publications
55
860
5
5
Order By: Relevance
“…Hence, EMT status may be a valuable marker for predicting EGFR-TKI treatment response in the EGFR wild-type group. This hypothesis has been investigated and confirmed in several in vitro and in vivo studies (36)(37)(38)(42)(43)(44). One example is a retrospective analysis of 99 patients with wild-type EGFR where EMT status was evaluated using a combined IHC-score for E-cadherin, N-cadherin, fibronectin and vimentin and showing that EMT status is a predictive factor for experiencing an objective response or stable disease during EGFR-TKI treatment (epithelial 23.5%, mesenchymal 2.4%) (38).…”
Section: Treatment Response In Egfr Wild-type Patientsmentioning
confidence: 82%
“…Hence, EMT status may be a valuable marker for predicting EGFR-TKI treatment response in the EGFR wild-type group. This hypothesis has been investigated and confirmed in several in vitro and in vivo studies (36)(37)(38)(42)(43)(44). One example is a retrospective analysis of 99 patients with wild-type EGFR where EMT status was evaluated using a combined IHC-score for E-cadherin, N-cadherin, fibronectin and vimentin and showing that EMT status is a predictive factor for experiencing an objective response or stable disease during EGFR-TKI treatment (epithelial 23.5%, mesenchymal 2.4%) (38).…”
Section: Treatment Response In Egfr Wild-type Patientsmentioning
confidence: 82%
“…The molecular signature of EMT is a good predictor of chemo-resistance and neoplastic disease lethality [112][113][114][115][116]; thus, EMT gene expression signature predicts chemo-resistance to EGFR and PI3K inhibitors in nonsmall cell lung-carcinoma (NSCLC) cells [113]. It has also been proposed that the ongoing EMT signature predicts the systemic recurrence of tumoral development in breast cancer [117].…”
Section: Adora2amentioning
confidence: 99%
“…While loss of E‐cadherin expression represents a primal event in EMT, we increasingly appreciate that EMT is a complex process that is orchestrated by activation and repression of a growing and still incomplete list of genes, proteins, and transcriptional factors including ZEB1, SNAIL, TWIST, CDH2, and VIM among others 5, 6, 7. Although several different EMT‐related gene expression signatures (GES) have been reported to date attempting to capture key EMT‐associated genes and regulators of EMT, they have been limited in part by variations observed between cell lines, limited concordance between different EMT induction models, and lack of functional validation 8, 9, 10, 11, 12. Therefore, additional studies are still needed to identify both a robust, common set of EMT‐associated genes and regulators in order to help improve our understanding of EMT, which could serve to drive future prognostic approaches and individualized therapies.…”
Section: Introductionmentioning
confidence: 99%